- Merck & Co Inc MRK has agreed to acquire Imago BioSciences Inc IMGO for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
- "This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," commented Merck's President & CEO, Robert Davis.
- Imago is a clinical-stage biopharmaceutical company developing new medicines for myeloproliferative neoplasms (MPNs) and other bone marrow diseases.
- Related: Centre Piece Of Merck's $11.5B Acceleron Buyout Aces Late-Stage Cardiovascular Trial.
- Imago's lead candidate, bomedemstat (IMG-7289), is currently being evaluated in multiple Phase 2 clinical trials for essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications.
- The transaction is expected to close in the first quarter of 2023.
- In July 2021, Imago closed its initial public offering with $134.4 million in gross proceeds and $20.0 million from its concurrent private placement.
- Earlier this year, Merck said it was in advanced talks to acquire Seagen Inc SGEN, and an agreement on a purchase was expected in the next few weeks.
- However, there is no update on the Merck/Seagen deal.
- Price Action: IMGO shares are up 104.90% at $35.65 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
